Esophageal

ECOG E2208 Randomized Phase II Study of Paclitaxel with or without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer

USO 08183- A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery .

 Please contact the NYOH Research Department for more information on clinical trials at (518) 489-0044 ext. 1239